Back to search

Article

Efficacy and safety of dexamethasone sparing for the prevention of nausea and vomiting associated with moderately emetogenic chemotherapy: A systematic review and meta-analysis of Clinical Practice Guidelines for Antiemesis 2023 from Japan Society of Clinical Oncology

2024-10-15

Abstract excerpt

<title>Abstract</title> <p>Background Palonosetron, a second-generation 5-HT<sub>3</sub> receptor antagonist (5-HT<sub>3</sub>RA), is more effective than first-generation 5-HT<sub>3</sub>RA. Several studies have investigated whether dexamethasone (DEX), when combined with palonosetron as a 5-HT<sub>3</sub>RA, can be spared in the delayed phase after moderately emetogenic chemotherapy (MEC). In this systematic re...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
3482be09-f3d2-54b1-bfbc-b82a82c79667
DOI
10.21203/rs.3.rs-4845344/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Efficacy and safety of dexamethasone sparing for the prevention of nausea and vomiting associated with moderately emetogenic chemotherapy: A systematic review and meta-analysis of Clinical Practice Guidelines for Antiemesis 2023 from Japan Society of Clinical OncologyDOI 10.21203/rs.3.rs-4845344/v1
A multicenter, phase II trial of triplet antiemetic therapy with palonosetron, aprepitant, and olanzapine for highly emetogenic chemotherapy in breast cancer (PATROL-II)Semantic proximity
5-Hydroxytryptamine-3 Receptor Antagonist and Dexamethasone as Prophylaxis for Chemotherapy Induced Nausea and Vomiting during Moderately Emetic Chemotherapy for Solid Tumors: A Multicenter, Prospective, Observational StudySemantic proximity
Association of ABCB1, 5-HT3B receptor and CYP2D6 genetic polymorphisms with ondansetron and metoclopramide antiemetic response in Indonesian cancer patients treated with highly emetogenic chemotherapy.Semantic proximity
Comparison of granisetron and palonosetron in triplet anti-emetic prophylaxis in non-small cell lung cancer patients receiving cisplatin-based highly emetogenic chemotherapySemantic proximity
Successful Dexamethasone Dose Reduction During Weekly Paclitaxel/Carboplatin with Chemoradiotherapy: Two Delirium-Associated CasesSemantic proximity
Delayed chemotherapy-induced nausea – Occurrence and corelates in an international multi-center study in adult oncology patients in clinical practice (CINrate)Semantic proximity
Studying the Incidence of Nausea and Vomiting after General Anesthesia and Determining the Risk FactorsSemantic proximity
Effects of sugammadex versus neostigmine on postoperative nausea and vomiting in adult patients after general anesthesia: A single-center retrospective studySemantic proximity
Comparison of three different prophylactic treatments for postoperative nausea and vomiting after total joint arthroplasty under general anesthesia: a randomized clinical trialSemantic proximity
Study on anaesthetic agent propofol and sevoflurane as maintenance agent along with anti-emetic drug ondansetron in reducing post operative nausea and vomiting in high-risk patientsSemantic proximity
An Update in Our Understanding of the Relationships Between Gene Polymorphisms and Chemotherapy-Induced Nausea and VomitingSemantic proximity
Genetic Risk Factors Associated With Antiemetic Efficacy of Palonosetron, Aprepitant, and Dexamethasone in Japanese Breast Cancer Patients Treated With Anthracycline-based Chemotherapy.Semantic proximity
Select a neighboring publication to make it the new centre.